O desenvolvimento embrionário tem inicio a partir da fecundação do oócito pelo espermatozóide no interior do oviduto. O oviduto é um órgão tortuoso que mede de 20 a 30cm e está dividido em três porções: istmo, ampola e infundíbulo. Os hormônios influenciam a atividade das células-alvo pela ligação de moléculas receptoras especificas. A imuno-histoquímica é o conjunto de procedimentos que utiliza anticorpos como reagentes específicos para detecção de antígenos presentes em células ou tecidos, portanto, através desta técnica é possível verificar a presença de receptores hormonais em determinados órgãos. Este estudo teve como objetivo localizar a presença de receptores para o hormônio luteinizante (LH) nas diferentes porções do oviduto utilizando a técnica de imuno-histoquímica. Foram utilizadas 18 éguas que se encontravam em estro, ou seja, apresentavam um folículo maior que 35mm e trato reprodutivo condizente com a fase estrogênica do ciclo estral. Das 18 éguas utilizadas neste trabalho, 16 éguas (88,8 %) apresentaram receptores para hormônio luteinizante (RLH) no oviduto. Destas 16 éguas, 8 (44,4 %) apresentaram RLH no epitélio e 7 (38,8 %) apresentaram RLH no tecido muscular do istmo, 14 (77,7 %) apresentaram RLH no epitélio e 13 (72,2 %) no tecido muscular da ampola, 10 (55.5 %) apresentaram RLH no epitélio e 1 (5,5 %) no tecido muscular do infundíbulo. Nas éguas que apresentaram receptores no epitélio a intensidade verificada foi de 1,5; 2,5 e 2,6 no istmo, ampola e infundíbulo, respectivamente enquanto que na porção muscular foi de 1,14; 2,3 e 3 respectivamente, para cada uma das três porções estudadas. Foi verificada uma maior intensidade de receptores na ampola do oviduto, o que pode relacionar o LH no processo de fecundação do oócito pelo o espermatozóide. / Embryonic development begins with the fertilization of the egg by the sperm in the oviduct. The oviduct is a tortuous organ which extended measures 20 to 30cm and is divided into three parts: the isthmus, ampulla and infundibulum. Hormones influence the activity of target cells by binding to specific receptor molecules. Immunohistochemistry is the set of procedures that use antibodies as reagents for detection of specific antigens present in cells or tissues, therefore, using this technique it is possible to verify the presence of hormone receptors in certain organs. This study aimed to verify the presence of hormone receptors for luteinizing hormone (LH) in different portions of the oviduct using the technique of immunohistochemistry. We used 18 mares were in estrus that had a follicle greater than 35mm and reproductive tract consistent with the estrogen phase of the estrous cycle. From the 18 mares that were part of that study, 16 mares (88.8 %) had receptors for luteinizing hormone (RLH) in the oviduct. From these 16 mares, 8 (44.4 %) had RLH in the epithelium and 7 (38.8 %) had RLH in the muscle of the isthmus, 14 (77.7 %) had RLH epithelium and 13 (72.2 %) in the muscle of the ampulla, 10 (55.5 %) had RLH in the epithelium m and 1 (5.5 %) in the muscle of the infundibulum. In mares that had receptors in the epithelium the intensity verified was 1,5 ; 2,5 and 2,6 on the isthmus, ampulla and infundibulum, respectively while in the muscular portion was 1,14 ; 2,3 and 3 respectively, for each of the three portions studied. It was verified a greater intensity of receptors in the ampulla of the oviduct, which may relate the LH in the process of fertilization of the oocyte by the sperm.

Anti-oestrogens act via the oestrogen receptor whether they compete with the hormone for binding to the receptor and therefore interfere with DNA binding or inhibit transcriptional activity. These receptors exist as a large 85 complex and/or a small 45 form on sucrose density gradients. High performance ion-exchange chromatography has confirmed that the oestrogen and progestin complex is present in various isoforms. Progestin receptor heterogeneity could be influenced by the presence of oestrogens and anti-oestrogens in the culture media of hormone-dependent neoplastic cells. Cell culture methods offer the opportunity to test effects of specified components in repeated experiments on a homogeneous population of cells. MCF-7 and T47-D human breast cancer cell lines were conditioned to grow in a serum-free environment. There was no difference in cell proliferation rates, nor in their oestrogen or progestin receptor levels when compared to the same cells grown in conventional media. Receptors were present mainly in the large molecular 85 form. Both the MCF-7 and T47-D breast cancer cells showed an increase in proliferation rate with the addition of oestrogen or diethylstilbestrol. There was a corresponding loss of progestin receptor levels and an alteration in the high performance ion-exchange isoforms. Flow cytometry confirmed differences in the S-phase components of the cells following exposure to oestrogens. The proliferation rates of the cell lines as well as their progestin receptor levels decreased when treated with tamoxifen or the hydroxylated tamoxifen. There were marked changes on high performance ion-exchange chromatography profiles. DNA ploidy and S-phase showed signs of toxicity and there was an increase in cellular debris. The MCF-7 and T47-D human breast cancer cell line retained response to antioestrogen saturation.

Vasoconstriction can be initiated via the interaction of a number of chemicals with specific "receptive sites" known as the receptors. This thesis examines two distinctly different modes by which drugs initiate a contractile response, namely, (i) the interaction of angiotensin analogues with a heterogeneous population of angiotensin receptors in vascular smooth muscles, and (ii) the conditions whereby B-adrenoceptor antagonists interact with a-adrenoceptor antagonists thereby causing a pressor response. Conscious, unrestrained, instrumented-rats were used for the study. It has been suggested that angiotensin receptors in vascular and non-vascular tissues may not be of a homogeneous population. The first study examined whether a heterogeneous population of angiotensin receptors was responsible for increasing vascular tone. Dose-response curves were constructed for angiotensin II (ANG II) and des Asp¹ angiotensin II (ANG III) on mean arterial pressure (MAP) and mean circulatory filling pressure (MCFP), an index of total body venous tone, in the presence or absence of [Sar¹, Ile⁸]ANG II. The i.v. infusion of ANG II or ANG III caused dose-dependent increases in MAP and MCFP. In the presence of [Sar¹, Ile⁸]ANG II, the MAP and MCFP curves for ANG II were displaced to the right with pA₂ values of 9.2 and 8.4 for the arterioles and veins, respectively. However, the antagonist displaced dose-MCFP but not the dose-MAP response curve of ANG III. This suggests that ANG II and ANG III act on the same receptor in veins but not arterioles. This concept was further investigated by obtaining dose-MAP and dose-MCFP response curves for ANG II in the presence of ANG II or ANG III. Dose-MAP response curve to ANG II was displaced to the right in the presence of ANG II but not ANG III. Dose-MCFP response curve for ANG II was displaced to the right in the presence of ANG III but not ANG II. These results again suggest that ANG III acts on the same receptors as ANG II in the veins but not arterioles. In the last series of experiments two analogues of angiotensin III were compared as antagonists of the pressor response to ANG II and ANG III. In the presence of [Ile⁷]ANG III, the dose-MAP response curves for ANG II and ANG III were displaced to the right while in the presence of [Sar¹, Ile⁷]ANG III, the dose-MAP response curve for ANG III but not ANG II was displaced. This suggests that [Sar¹, Ile⁷]ANG III is a selective antagonist of ANG III in the arterioles. In summary, the results indicate that ANG III acts on a different sub-class of angiotensin receptors than ANG II in the arterioles but it may act as a partial agonist on the same type of receptors as ANG II in the venous bed. Thus, ANG II receptors in the arterioles appear to be different from those in veins. The administration of a non-selective β-antagonist propranolol into animals subjected to non-selective α-blockade has been observed to cause a paradoxical pressor response. This second study examines whether the paradoxical pressor response to β-antagonists was due to: (i) an interaction of a β-antagonist with an α-antagonist, (ii) blockade of vasodilator β₂-adrenoceptors or (iii) an increase in the release of catecholamines. Cumulative dose-response curves for propranolol, atenolol (β₁-antagonist) and ICI 118,551 (β₂-antagonist) were obtained in rats subjected to a continuous i.v. infusion of phentolamine, a non-selective α-antagonist. The administration of each of the β-antagonists caused a dose-dependent increase in MAP suggesting that the pressor response was not due to the blockade of vasodilator β₂-adrenoceptors. Another four groups of phentolamine-treated rats were given a single i.v. bolus injection of saline, propranolol, atenolol or ICI 118,551, and sampling of arterial blood for the determination of adrenaline (A) and noradrenaline (NA) concentration by HPLC/ec. Phentolamine caused a decrease in MAP and an increase in the plasma levels of A and NA. Subsequent injection of propranolol, atenolol and ICI 118,551 but not saline increased MAP. Neither saline nor any of the β-antagonists increased plasma NA or A levels suggesting that the pressor response was not associated with an acute increase in the release of catecholamines. It was also shown that prior injection of a β-antagonist partially antagonized the hypotensive effect of phentolamine suggesting that the pressor response was related to an interaction between α- and β-antagonists. It was further shown that a continuous infusion of either prazosin or rauwolseine caused a small but not significant decrease in MAP which was reversed by propranolol. Concurrent infusions of prazosin and rauwolscine caused a large decrease in MAP. Subsequent injection of propranolol caused a large pressor response. On the contrary, sodium nitroprusside or metha-choline each decreased MAP but the hypotension was not antagonized by propranolol. These results were consistent with the existence of a specific interaction between α- and β-antagonists. These experiments demonstrated that although the mechanisms involved in the initiation of a change in vascular tone did not share a common pathway, the final outcome shared a common denomination. / Medicine, Faculty of / Anesthesiology, Pharmacology and Therapeutics, Department of / Graduate

A novel bacterial expression system that is capable of producing high levels of soluble, stable, biologically active human vitamin D3 and estrogen receptors has been developed. The method utilizes ubiquitin fusion technology and a low temperature nalidixic acid induction of the lambda PL promoter. This system can produce large quantities of receptor antigen, but only a small fraction displays wild-type DNA and hormone binding properties. Therefore, the use of this system to overproduce receptors for crystallization studies is not practical. To overcome these problems, a 2 um based ubiquitin fusion system which allows regulated expression of the estrogen receptor in yeast (Saccharomyces cerevisiae) was developed. This system produces the estrogen receptor to a level of 0.2% of the total soluble protein. Moreover, this protein is undegradable, soluble, and biologically active. To test the transcriptional activity of the estrogen receptor produced in yeast, a cis-trans transcription assay was developed. This assay revealed that the transcriptional activity of the human estrogen receptor expressed in yeast was similar to that observed in transfected mammalian cells. This reconstituted estrogen transcription unit in Saccharomyces cerevisiae was utilized to examine the regulation of estrogen receptor functions by antiestrogens, to develop a random and rapid approach for identifying novel estrogen response elements, to characterize estrogen receptor variants cloned from human breast tumors, and to examine the effect of estrogen receptor on the regulation of osteocalcin gene.

No description available.

Traumatic brain injury (TBI) is a major cause of hospitalization and death. To mitigate these human costs, the search for effective drugs to treat TBI continues. Even mild injuries can lead to long-term deficits in memory and cognition. Predicting which patients will have long lasting memory issues following mild TBI is challenging. Our group has previously shown that in vitro models of TBI result in cell death, decreased long-term potentiation (LTP), and glial activation. In this thesis, we used chemical and electrical treatments to modulate the outcome following injury to inform future therapies. In the first aim of this thesis, we evaluated the efficacy of a novel neurosteroid, NTS-105, to reduce post-traumatic pathobiology in an in vitro model of moderate TBI that utilizes an organotypic hippocampal slice culture. Treatment with NTS-105 starting an hour after injury decreased post-traumatic cell death in a dose-dependent manner, with 10 nM NTS-105 being most effective. Post-traumatic administration of 10 nM NTS-105 also prevented deficits in LTP without adversely affecting neuronal activity in naïve cultures. Our results suggest that the pleiotropic pharmacology (affinity for the androgen, mineralocorticoid, and progesterone receptors) of NTS-105 may be a promising strategy for the effective treatment of TBI. In the second aim, we evaluated the mechanisms of NTS-105 in an in vitro model of mild blast TBI, a model in which NTS-105 is known to preserve LTP. Treatment with NTS-105 starting an hour after injury reduced a marker of microglial activation and increased expression of the GluR1 subunit of the AMPAR, which is a postsynaptic protein associated with LTP. NTS-105 is known to inhibit activation of the androgen receptor and the mineralocorticoid receptor, partially activate the progesterone B receptor and not activate the glucocorticoid receptor. NTS-105 treatment did not alter the expression of any of the oxosteroid receptors (progesterone, androgen, mineralocorticoid, and glucocorticoid). In order to demonstrate the benefits of mineralocorticoid antagonism following TBI, we administered eplerenone immediately after injury. Eplerenone treatment preserved LTP, but did increase spike magnitude at high concentrations. In the third aim, organotypic hippocampal slice cultures were biaxially stretched to model a mild TBI and serial electrophysiological recordings were collected. In this in vitro model, stretchable microelectrode arrays were embedded within the culture substrate to both deform the adhered culture and record neural signals, which are indicators of neuronal health and network connectivity. Multiple spontaneous and evoked recordings were obtained while maintaining sterility to study and modulate the electrophysiological response to injury. Bursting activity increased 2 hours after injury but returned to baseline by 24 hours. However, 24 hours after injury, both LTP and long-term depression (LTD) were impaired. In another experiment, LTP was induced multiple times, both 24 hours before and 24 hours after injury, to study how the state of the pre-injury network affected electrophysiological outcome after injury. We provide preliminary evidence that induction of LTP before injury to increase synaptic strength was detrimental to neuronal plasticity (LTP) after injury. This thesis has expanded upon the understanding of TBI injury mechanisms and hormone receptor modulators following TBI. Future studies will continue to examine NTS-105 and study the benefits of androgen receptor antagonism. Future studies will also continue to use the stretchable microelectrode arrays and our induction paradigm to test if induction of LTD, a weakening of synaptic strength, could increase resiliency to injury.

Master of Science / Department of Entomology / Yoonseong Park / Neuropeptides are diffusible signal molecules mediating vital physiological processes. We have been interested in a group of neuropeptides and their receptors involved in osmoregulatory neuroendocrine system which has been suggested as a possible target for development of new biopesticides. Since the genome sequence of the T. castaneum has recently been completed, we were able to identify the respective genes encoding three peptide hormones from T. castaneum that were characterized for their diuretic activities in other insects: one calcitonin-like (CT-like DH31) and two corticotropin releasing factor-like (CRF-like DH37 and DH47, the numbers indicates the number of amino acid residues). This peptide is expressed at all developmental stages and in the central nervous system (CNS), Malpighian tubules (MT) and gut. The synthetic peptide TricaDH31 also has been show to be biologically active, inducing significant excretions in adults beetles. When Tcdh31 was silenced using RNAi, adults had deformed wings and abnormal body shape. Mortality in adults was high, the number of eggs laid was reduced as well as the hatchability of the eggs. The two biologically active CRF-like peptides in T. castaneum, are encoded by one gene which undergoes alternative splicing. When Tcdh47 was knocked down, high mortality occurred as well as low oviposition and egg hatchability. Similar effects were observed with silencing of both CRF-like genes. However, RNAi of Tcdh37 transcripts had similar, but less severe effects. Adults also had deformed wings when both CRF-like genes were silenced, but not when just one of them was knocked down. These results indicate that CRF-like genes could have additional biological functions to their roles in dieresis. We tested the in vivo activity of these peptides. TenmoDH47 induced high excretions in adults, whereas TenmoDH37 induces smaller excretions. We identified the respective genes encoding two putative receptors for TricaDH31 as Glean_13321 and Glean_02694 (Trica-ctr1 and Trica-ctr2, respectively) and two receptors for CRF-like peptide as Glean_12799 and Glean_07104 (Trica-crfr1 and Trica-crfr2, respectively). The CT-like receptors are expressed at all developmental stages, in the CNS and MT. RNAi of the receptors revealed that only Trica-ctr2 silencing caused significant mortality and reduction in the number of eggs laid. The CRF-like receptors are expressed at all developmental stages. Adults also had deformed wings and laid fewer eggs after RNAi of Trica-crfr1. RNAi of Trica-crf2 also caused significant mortality. These peptides and receptors seem to fine tune the beetle physiology and may have functions not yet known.

published_or_final_version / abstract / Pathology / Master / Master of Philosophy

Research Doctorate - Doctor of Philosophy (PhD) / Endometrial cancer is one of the most common female cancers in industrialized countries. Traditional risk factors associated with endometrial cancer are well understood and include excessive exposure to estrogen or estrogen unopposed by progesterone. However, variations in the genes that influence these hormones and their association with endometrial cancer have not been well investigated. By studying genetic variation in endometrial cancer, novel markers of risk may be discovered that can be used to identify women at high risk and for the implementation of specialised treatments. Polymorphisms in the genes involved in the following pathways; hormone biosynthesis, hormone receptors, estrogen metabolism, DNA repair and cell cycle control, have been suggested to be involved in the initiation and development of endometrial cancer. The focus of this study was to examine genetic variants in these pathways to assess the existence of an association with the risk of endometrial cancer. In the first part of this study, the COMT V158M polymorphism was examined in a hereditary non-polyposis colorectal cancer (HNPCC) cohort to determine its association with disease expression. The heterozygous genotype was over-represented in women with endometrial/ovarian cancer that did not harbour mismatch repair (MMR) gene mutations. This result suggested that the COMT V158M polymorphism may alter the risk of developing HNPCC related endometrial/ovarian cancer in MMR mutation negative women. Since COMT is involved in the metabolism of estrogen and that estrogen is the main risk factor for endometrial cancer development, closer examination was warranted to determine the association of genetic variation involved in hormone-related pathways and endometrial cancer risk, outside of the context of an inherited predisposition to disease. In the second part of this study, a cohort of 191 women with endometrial cancer and 291 healthy control women were genotyped for polymorphisms in genes involved in hormone biosynthesis, hormone receptors, estrogen metabolism, DNA repair and cell cycle control. The results revealed that variations in estrogen receptor alpha (ESR1) and beta (ESR2), and the androgen receptor (AR), were associated with an increase and decrease in endometrial cancer risk, respectively. Additionally, polymorphisms in CYP1A1, CYP1B1, GSTM1 and GSTP1 were related to a decrease in endometrial cancer risk. A trend was observed for the cyclin D1 870 G>A polymorphism and an increase in endometrial cancer risk, however, this result did not reach significance. Taken together, these results revealed that perturbations in the hormone receptors and estrogen metabolism genes, may aid in the identification of women at high risk of developing endometrial cancer. Interestingly, stratification of the women with endometrial cancer revealed that combinations of polymorphisms in TP53 and MDM2 were associated with higher grades of cancer. This finding may possibly have significant implications as women with reduced apoptotic ability, due to combinations of polymorphisms in these genes, have an increased risk of presenting with higher grades of endometrial cancer, that are associated with lower survival rates. In summary, the results of this thesis showed that variation in the estrogen and androgen receptors, and estrogen metabolism genes, may alter the risk of developing endometrial cancer. Moreover, polymorphisms in the cell cycle control genes, TP53 and MDM2, appear to be associated with higher grades of endometrial cancer. This study of polymorphisms may help explain genetic differences in individual susceptibility to endometrial cancer and are markers of risk that aid in the development of effective and personalised strategies to prevent disease development. This study has improved the understanding of genetic variation associated with endometrial cancer risk. It has the potential to enhance our ability to treat women with endometrial cancer through improved identification and treatment strategies, by virtue of the genetic variation identified, that appears to predispose to disease.

Thesis (Ph. D.)--University of Washington, 2007. / Vita. Includes bibliographical references (p. 133-145).